MULTIVALENT CORONAVIRUS BINDING MOLECULES AND USES THEREOF

Described herein are synthetic multivalent binding molecules that bind to a coronavirus polypeptide, e.g., the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete with receptor binding to inhibit coronavirus infection. Also described are multivalent binding molecules that bind to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MIERSCH, Shane, ADAMS, Jarrett J, RINI, James Michael, LI, Zhijie, BLAZER, Levi Lynn, USTAV, Mart, SIDHU, Sachdev
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Described herein are synthetic multivalent binding molecules that bind to a coronavirus polypeptide, e.g., the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete with receptor binding to inhibit coronavirus infection. Also described are multivalent binding molecules that bind to the SARS-CoV-2 receptor binding domain (RBD) and exhibit neutralization potencies at sub-nanomolar concentrations against SARS-CoV-2/USA/WA1 in Vero E6 cells. L'invention concerne des molécules de liaison multivalentes synthétiques qui se lient à un polypeptide de coronavirus, par exemple à la protéine de spicule du SARS-CoV-2 (l'agent provoquant la COVID-19), concurrençant la liaison au récepteur de manière inhiber l'infection à coronavirus. L'invention concerne également des molécules de liaison multivalentes qui se lient au domaine de liaison au récepteur (RBD) du SARS-CoV-2 et présentent des capacités de neutralisation à des concentrations sous-nanomolaires contre le SARS-CoV-2/USA/WA1 dans des cellules Vero E6.